15 JULY 2024

Act 342 Amendments: Risk of Double Standards, Victimisation, & Poor Outcomes

We saw much of this occurring during the COVID-19 crisis.

11 JULY 2024

Earmarked Vape Tax Revenue Needed To Reverse Effects of Nicotine Deregulation

Promised taxes have not been earmarked for health related initiatives.

5 JULY 2024

Co-Payments Will Cause Jump in OPP & Fail To Address Healthcare Inflation

Will this really address healthcare inflation?

The Galen Centre for Health and Social Policy is an independent public policy research and advocacy organisation.

What do we think about key health and social issues?

4 JUNE 2024

Reforms to the IHR: Malaysia Should Establish A Health Security Agency

This agency is a necessary investment.

31 MAY 2024

WNTD 2024: Nicotine Vape & E-Cigarettes Join Cigarettes As Public Health Threats

Five measures are recommended.

19 MAY 2024

NHMS 2023 Findings Should Be A Rude Wake-up Call For Malaysians

Malaysians are currently living amidst a NCD crisis.

9 MAY 2024

Sugar Should No Longer Be A Controlled Item Under PCAP Act 2011

Malaysia currently has one of the lowest sugar prices in the world. This is not something to be proud of.

1 APRIL 2024

Nicotine Vape Delisting: A Health Minister’s Legacy

Concerns and warnings were noted, but not heeded.

15 MARCH 2024

Proposed Amendments of Citizenship Provisions Will Worsen Health inequities

This policy could dramatically increase health security risk and vulnerabilities.

CRM2023_1

Event Recordings

This session is Part 2 of the Health Economics for Rare Diseases Workshop previously held on 22 November. Prof. Rob Baltussen of Radboud Universiteit, Netherlands continues the conversation with a discussion on the use of multiple-criteria decision analysis for decision making on rare diseases. This session is Part 2 of the Health Economics for Rare Diseases Workshop previously held on 22 November. Prof. Rob Baltussen of Radboud Universiteit, Netherlands continues the conversation with a discussion on the use of multiple-criteria decision analysis for decision making on rare diseases. Speaker background Prof. Rob Baltussen is an economist specialized in global health economics. His research focuses on the development of methods and tools for priority setting in health, to support Ministries of Health to make socially acceptable choices. For this, Baltussen integrates methods from various disciplines such as economics, ethic and decisions, which resulted in the development of ‘evidence-informed deliberative processes’ (EDPs). He has also led the citizen forum on ‘Choices in health care’ which was held in the Netherlands in 2017. Presently, Baltussen and his team are supporting several Minisatries of Health around the world through the implementation of EDP, including in the Netherlands, Ghana, Indonesia, Iran, Kazachstan, Tanzania and Moldova. Baltussen was Chair of the International Society for Priorities in Health 2016-2018. He has extensive field work experience in around 25 countries in Africa and Asia, and worked as a senior health economist at the World Health Organization in Geneva being responsible for the development of WHO guidelines on cost-effectiveness analysis. Prof. Rob Baltussen is an economist specialized in global health economics. His research focuses on the development of methods and tools for priority setting in health, to support Ministries of Health to make socially acceptable choices. For this, Baltussen integrates methods from various disciplines such as economics, ethic and decisions, which resulted in the development of ‘evidence-informed deliberative processes’ (EDPs). He has also led the citizen forum on ‘Choices in health care’ which was held in the Netherlands in 2017. Presently, Baltussen and his team are supporting several Minisatries of Health around the world through the implementation of EDP, including in the Netherlands, Ghana, Indonesia, Iran, Kazachstan, Tanzania and Moldova. Baltussen was Chair of the International Society for Priorities in Health 2016-2018. He has extensive field work experience in around 25 countries in Africa and Asia, and worked as a senior health economist at the World Health Organization in Geneva being responsible for the development of WHO guidelines on cost-effectiveness analysis.
En. Syed Johari Syed Jamaludin, an ILD patient, shares his experience being diagnosed and treated for interstitial lung disease treatment, as well as the challenges faced throughout his journey. This presentation was part of the symposium "Interstitial Lung Disease in Malaysia: Addressing awareness, treatment and care, and unmet needs" organised by the Galen Centre of Health and Social Policy on 21 October 2022. Held with the support of Boehringer Ingelheim, the symposium discussed the state of care for interstitial lung disease (ILD) in Malaysia, as part of preparations to develop a White Paper on this condition.
Dr Noorul Afidza Muhammad, a pulmonologist with Hospital Serdang presents an update on clinical trials related to interstitial lung disease treatment. This presentation was part of the symposium "Interstitial Lung Disease in Malaysia: Addressing awareness, treatment and care, and unmet needs" organised by the Galen Centre of Health and Social Policy on 21 October 2022. Held with the support of Boehringer Ingelheim, the symposium discussed the state of care for interstitial lung disease (ILD) in Malaysia, as part of preparations to develop a White Paper on this condition.

Our Focus Areas

Healthcare Reform

We look at how institutional reforms can create an adaptive and sustainable healthcare system and social care, capable of delivering integrated models of care to meet the challenges of our developing society.

Non-Communicable Diseases

Non-communicable diseases (NCDs) are emerging as the leading cause of death in Malaysia. About two-thirds of Malaysians have at least one NCD. What policies and interventions are needed in response?

Food Security

We look at the linkages of food security with health, sustainable economic development, environment, social justice and trade.

 

 

Transgender Health

Transgender people face numerous health disparities, stigma, discrimination, and lack of access to quality care. How do medical institutions, communities and individuals respond to their care?